Abstract: The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase.

Abstract: The present invention provides an antitumor agent comprising cisplatin and a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent life-prolongation effect in advanced gastric cancer patients that is superior to that of the standard therapy in Europe and the U.S. using an agent that contains 5-FU and does not contain a dihydropyrimidine dehydrogenase inhibitor, by way of selecting the patients based on dihydropyrimidine dehydrogenase.

Abstract: The present invention provides an antitumor agent or postoperative adjuvant chemotherapeutic agent for a hepatocellular carcinoma patient who has been treated by transarterial embolization. An antitumor agent or postoperative adjuvant chemotherapeutic agent comprising TSU-68 or a salt thereof, which can be administered to a hepatocellular carcinoma patient within 2 weeks after transarterial embolization, is provided.

Abstract: The present invention provides a method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients who have been treated with transarterial embolization and an antitumor agent for treating cancer patients who have been predicted to have a high probability of obtaining sufficient therapeutic effects from such chemotherapy. The present invention also provides a method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients who have been treated with transarterial embolization using the expression level of PDGF-BB or IL-8 as an indicator and an antitumor agent for treating cancer patients who have been predicted to have a high probability of obtaining therapeutic effects by such prediction method.

Abstract: The present invention provides an antitumor agent comprising cisplatin and a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent life-prolongation effect in advanced gastric cancer patients that is superior to that of the standard therapy in Europe and the U.S. using an agent that contains 5-FU and does not contain a dihydropyrimidine dehydrogenase inhibitor, by way of selecting the patients based on dihydropyrimidine dehydrogenase.

Abstract: The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase.

Abstract: The present invention provides an animal model for use in the development of a preventive or therapeutic agent for human chronic nonbacterial prostatitis, in particular a nonbacterial prostatitis nonhuman animal model mimicking the pathology of human chronic nonbacterial prostatitis. The nonbacterial prostatitis animal model is prepared by injecting hydrochloric acid beneath the prostatic capsule and exhibits prostate tissue damage and lower urinary tract disorders that are characteristically observed in human chronic nonbacterial prostatitis.

Abstract: The present invention provides a sulfated polysaccharide (D-HG), a pharmaceutically acceptable salt thereof, a process for preparing the same and a medicament containing the same as the effective component for DIC (disseminated intravascular coagulation) and thrombosis, the sulfated polysaccharide (D-HG) being prepared by depolymerization of FGAG (a sulfated polysaccharide extracted from a body wall of a sea cucumber with such activities as those of heparin) or a salt thereof and having the following physicochemical properties:[1] Molecular weight:3,000 to 42,000 (as measured by high performance GPC)[2] Characteristic:white, amorphous, highly hygroscopic powder[3] Solubility:soluble in water but insoluble in ethanol, acetone and like organic solvents[4] Specific rotation:[.alpha.].sub.D.sup.20 =-55 to -73.degree.